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Transductionoflatentmembraneprotein2(LMP2)-speciﬁcT-cellreceptorsintoactivatedTlymphocytesmayprovideauniversal,
MHC-restricted mean to treat EBV-associated tumors in adoptive immunotherapy. We compared TCR-speciﬁc promoters of
distinct origin in lentiviral vectors, that is, Vβ6.7, delta, luria, and Vβ5.1 to evaluate TCR gene expression in human primary
peripheral blood monocytes and T cell line HSB2. Vectors containing Vβ 6.7 promoter were found to be optimal for expression
in PBMCs, and they maintained expression of the transduced TCRs for up to 7 weeks. These cells had the potential to recognize
subdominant EBV latency antigens as measured by cytotoxicity and IFN-γ secretion. The nude mice also exhibited signiﬁcant
resistance to the HLA-A2 and LMP2-positive CNE tumor cell challenge after being infused with lentiviral transduced CTLs. In
conclusion, LMP2-speciﬁc CTLs by lentiviral transduction have the potential use for treatment of EBV-related tumors.
1.Introduction
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus
associated with many human malignancies including a sub-
set of Hodgkin disease, Burkitt lymphoma, nasopharyngeal
carcinoma (NPC), and some gastric carcinomas [1–5]. The
malignancies associated with EBV can be grouped into 3
types according to the latency gene expressional proﬁles
[4–6]. In NPC, the EBV proteins expressed are EBNA1,
latent membrane protein 1 (LMP1), and LMP2 [7]. It has
been shown that all 3 antigens can induce CD8+ cytotoxic
T lymphocytes (CTLs), which play roles in antitumor
immune response [8, 9]. However, only weak responses
against EBNA1 can be detected in some individuals and the
phenotypic and functional analyses of these induced EBNA-
1-speciﬁc T cells revealed that EBNA1 is presented to CD4+
T helper as well as Treg cells, which suppress the antiviral
immune response. Moreover, the poor immunogenicity of
EBNA1 has also been attributed to the presence of a Gly-
Ala repeat (GAr) sequence, which prevents the presentation
of EBNA1-derived antigenic peptides by MHC class I
molecules.ThisGAr-mediatedfunctionhasbeenlinkedtoits
capacity to prevent EBNA1 synthesis, as well as proteasomal
degradation [10–13]. On the other hand, LMP-1 is the only
EBV protein with recognized oncogenic activity that can
transform normal cells into malignant ones, thereby limiting
its application as a potential immunotherapeutic target.
Additionally, the LMP1-speciﬁc CTL frequency is low, and
the reactivation of LMP1-speciﬁc CTL lines has been shown
very diﬃcult, in part because LMP1 is toxic when expressed
at high levels. In NPC, LMP2 oﬀers the best opportunity
for speciﬁc targeting since it is consistently expressed and2 Clinical and Developmental Immunology
the T-cell determinants in LMP2 sequence have been well
deﬁned [14–17]. Many studies, including clinical trials, have
proven LMP2 to be an ideal immunotherapeutic target and
inducer, which so far has not shown oncogenicity [16, 18–
20]. It has been shown that this antigen can be processed
by a proteasome system. The peptides are engaged in the
major histocompatibility complex (MHC) class I, then move
to the cell surface, and migrate to the CD8+ T cells on the
cell surface [21–24]. Many CD8+ T cell-recognizing epitopes
have been identiﬁed and most of them are conserved in NPC
cells among diﬀerent populations. Low LMP2 is a widely
used targeting molecule and antigen for the immunotherapy
of type II EBV-associated malignancies [19, 21, 25–29].
AdoptiveimmunotherapywithCTLsholdsgreatpromise
for the treatment of cancer. Among them, the treatment of
EBV-associated tumors has by far shown the most success
[26–28, 30, 31]. With the development of molecular and
cellular biology, tumor-speciﬁc CTLs can be selected and the
T cell receptor genes can be cloned into highly eﬃcient viral
vectors for transfer into the patient’s T cells. This concept has
been utilized since 1999, when Clay et al. transferred lytic
function by retroviral vectors encoding the α and β chains
of the TCR against EBV-associated tumors [32]. Today many
practitioners have designed and applied these engineered
CTLs for the treatment of various human malignancies [33–
37]. However, the eﬃcacy and eﬃciency of this application
still needs to be optimized, especially when using retro- or
lentiviral vectors for TCR transduction. These vector systems
can integrate transgenes into chromosomes that have the
potential to “immortalize” a normal cell. Thus, a speciﬁc T-
cell promoter that can be activated only in T cells becomes
critical for safety concerns. At the same time, transducing
eﬃciency should be considered when using both these viral
vectors.
In our investigation, we used an HLA-A2-restricted EBV
LMP2-speciﬁc TCR, TCR5.05, to compare 4 diﬀerent kinds
of T-cell-speciﬁc promoters: Luria, Delta [38], Vβ5.1 [39],
and Vβ 6.7 [40]. Our results show that all these T-cell-
speciﬁc promoters can drive the transcription of the TCR
gene without changing the transduced T cell phenotypes.
We also found that CTLs generated by a lentiviral vector
containing speciﬁc promoters and TCR genes can lyse target
cells speciﬁcally. We further evaluated the CTLs in vivo
and found that they can retard the growth of EBV-LMP2
expressing tumors and prolong the life of tumor-bearing
mice. We reported for the ﬁrst time that Vβ 6.7 promoter
is most eﬃcient when using the lentiviral vector to transduce
T cells for targeting HLA-A2-restricted EBV-LMP2 antigens.
This study may be helpful in designing and developing novel
TCR-based adoptive immunotherapy for the treatment of
EBV-associated tumors.
2.MaterialandMethods
2.1. Animals and Cell Lines. Six- to 8-week-old nude mice
were purchased and maintained in the SPF animal facility at
NanjingMedicalUniversity.Allproceduresusedinthisstudy
complied with institutional policies of the Animal Care and
Use Committee of Nanjing Medical University.
The cell lines used in these experiments included 293T,
HSB2 (human leukemic T-cell line); HLA-A2 restricted,
Epstein Barr virus-transformed B lymphoblastoid cell lines
(LCLs); K562; CNE (nasopharyngeal carcinoma cell line);
T2 cell lines (deﬁcient in TAP but still express low amounts
of MHC class I on the surface of the cells, kept in the
author’s lab). In animal model, CNE cells stably expressing
HLA-A2andLMP2wereestablishedbyplasmidpIRES/HLA-
A2/LMP2 transfection and selection. All cell lines were
cultured in RPMI 1640 plus 10% fetal bovine serum,
L-glutamine, nonessential amino acids, and penicillin-
streptomycin (100U/mL) (Invitrogen).
2.2. Construction of Lentiviral Vector Plasmids. TCR plasmid
PL5.05 and 4 T lymphocyte-speciﬁc promoters (PSK-
Delta/Vβ 5.1/Luria/Vβ 6.7) were kindly provided by
Rimas Orentas from Medical College of Wisconsin. EBV
LMP2-speciﬁc TCR cDNA we used was obtained from
T-cell clone which was generated by incubating HLA-
A2-restricted PBMC with peptide (CLGGLLTMV, LMP2:
426–434) as described by Orentas et al. [36]. TCR PL5.05
α and β chains were ampliﬁed by PCR using PL5.05 as a
template and cloned into 4 lentiviral vectors containing
various 4 T-cell promoters constructed from the parent
PWPT-GFP vector. The primers were α chain: Primer1A:
CAACGCGTCGGAATTCAGGCTCTCTTG; Primer2A-3A:
GTCATCGTCTTTGTAGTCGCTGGACCACAGCCGC;
CAGGTCGACTCACTTGTCGTCATCGTCTTTGTAGT; β
chain: Primer1B: ACTACGCGTCACCATGGCTATAGT-
GTCTCTAGATCAAAG; Primer2B-3B: TTCTGAGATGAG-
TTTTTGTTCCTAAAGGGAACAAAAGCTGGAAGTCGA-
CTCAATTCAGATCCTCTTCTGAGATGAGTTT. The α
and β were linked with Flag and Myc tag, respectively. All the
amplicons were sequenced and cloned into Mlu I and Sal I
sites of PWPT-GFP vectors.
2.3. Lentivirus Production. Lentiviruses were prepared by
transient transfection of 293T cells, using a liposomal
cotransfection method. To summarize, the 293 T cells were
seeded at 1 × 107 cells per 10-cm plate. The cells were
transfected 12–16 hours later with 20μg lentiviral transfer
vector, 12μg Delta 8.9, and 18μg VSV-G envelope plasmids
8.91 (Delta 8.9 and VSV-G envelope plasmids are helper
lentiviral plasmid which are used for packing lentivirus).
Forty-eight to 72 hours later, the supernatant was collected,
centrifuged to remove the cellular debris, and concentrated
approximately 30-fold by ultracentrifugation.
2.4. Determination of Lentiviral Titer. Titers of concentrated
lentivirus encoding green ﬂuorescent protein (GFP) were
determined by serially diluting and infecting 293T cells by
the polybrene transduction method as previously described
[41]. Titers (transducing units (TUs) GFP-positive cell
dilution factor) of the lentiviral vectors ranged from 106 to
107 TU/mL.
2.5. Transduction of PBMCs and T Cells. Peripheral blood
monocytes (PBMCs) were from an HLA-A2, healthy human.Clinical and Developmental Immunology 3
T cells were obtained from anti-CD3 conjugated magnetic
beads (Miltenyi Biotec, Bergish Glad-bach, Germany). The
PBMCs and T cells were cultured in AIM-V and interleukin-
2 (IL-2; PeproTech, Rocky Hill, NJ, USA) at 300IU/mL.
For OKT3 stimulation, the cells were placed initially in
either a medium with anti-CD3 antibody, OKT3 (Ortho
Biotech, Bridgewater, NJ, USA) at 50ng/mL or in an OKT3
medium after transduction at the initial changing of the
culture medium in the presence of IL-2. For transduction
of the PBMCs or T cells, 1 × 106 cells were adjusted to
a ﬁnal volume of 1mL in a 24-well, tissue culture-treated
plate with the viral supernatant and Polybrene (8mg/mL;
Sigma, St. Louis, Mo, USA). The cells were transduced by
centrifugation of the plates at 1000g for 1.5 hours at 32◦C.
T h ep l a t e sw e r ep l a c e di na3 7 ◦C, humidiﬁed, 5% CO2
incubator overnight, and the medium was replaced the next
day.
2.6.FlowCytometricAnalysis. CD3expressiononcellsurface
was measured with allophycocyanin-conjugated antibodies
and the corresponding isotype controls (BD Biosciences).
TCR PL5.05 staining was performed by using anti-TCR α
chain antibody (prepared from our lab) followed by phy-
coerythrin (PE)-labeled second antibody. Cells were stained
in a FACS buﬀer made of PBS (Invitrogen, Carlsbad, Calif,
USA) and 0.5% bovine serum albumin. Cells were collected
with a FACSCalibur ﬂow cytometer (BD Immunocytometry
Systems, San Jose, Calif, USA) and analyzed using CellQuest
software (BD Biosciences).
2.7. Real-Time PCR. After 3 days, total RNA was extracted
from the HSB2 cells which have been infected with len-
tivirus containing EBV-LMP2-speciﬁc TCR α and β chain
driven by Luria, Delta, Vβ 5.1, and Vβ 6.7 T-cell-specific
promoters. cDNA was reverse transcripted by a high-
capacity cDNA reverse transcription kit (ABI, Foster, Calif,
USA) using random primers. For α chain SYBR for-
ward primer: 5 -ctttcaaaacctgtcagtgattgg, reverse primer: 5 -
cagcgtcatgagcagattaaacc. For β chain SYBR forward primer:
5 -ggccaccttctggcagaac,reverseprimer:5 -agagcccgtagaactg-
gacttg. Real-time PCR with SYBR dyes was performed on
an ABI 7900 real-time machine and analyzed by SDS2.4
software.
2.8. Western Blotting. Fifty micrograms of total protein from
each sample was loaded for SDS-PAGE and subsequently
transferred onto the PVDF membranes. After blocking, the
membranes were hybridized with anti-Flag and Myc tag
antibodies, respectively. The membranes were washed and
incubated with secondary antibody, followed by developing.
2.9. Measurement of Lymphocyte Antigen Reactivity. Target
cells were prepared by using T2 cells pulsed with peptides
(10ng/mL) in cell culture medium or tumor cell lines for
2 hours at 37◦C and then washed twice in PBS. CD8+
T cells were isolated from lentiviral transduced PBMCs
using anti-CD8 beads from Miltenyi Biotec according to the
manufacturer’s protocol. For the assay, eﬀector cells (CD8+
T cells) and target (peptide-pulsed T2 or tumor cells) were
incubated in a 0.2-mL culture volume in the wells of a
96-well culture plate at E:T = 50:1, 25:1, and 5:1. The
cells were cocultured for 18 hours, and the supernatant was
harvested. The supernatants were analyzed for interferon
(IFN)-γ secretion, using a commercially available enzyme-
linked immunosorbent assay (ELISA) kit (Bender Medsys-
tem, Vienna, Austria). The supernatants were also measured
for LDH levels using a commercially available kit (Roche,
Boehringer Mannheim, Germany).
2.10. Mouse Immunization and Tumor Challenge. Tumor-
bearing model were established by injecting 1 ×106 HLA-A2
and LMP2-positive CNE cells subcutaneously in the ﬂank of
six- to 8-week-old nude mice. The mice were infused with
transduced CTL via tail vein 1 week after tumor cell injection
weekly for a total of two weeks. Mice immunized with the
mock or saline were used as a control. Tumor diameter
was measured by calipers twice per week and recorded as
the mean of narrowest and longest surface length for each
animal in the group. Mice were sacriﬁced when the tumor
size reached a 20mm average diameter. Each experiment was
performed at least twice, and results were essentially similar
unless described otherwise.
2.11. Statistical Analysis. Data are expressed as mean ± stan-
dard error of mean (SEM), as indicated in each experiment.
And the comparisons between the groups were made by
one-way ANOVA followed by unpaired t-test. A 4.0 version
(2005) of the GraphPad Prism software was used for this
purpose. Values of P<0.05 were considered signiﬁcant.
Survival curves were estimated using the Kaplan-Meier
method, and signiﬁcance was assessed using the log-rank or
the χ2 test.
3. Results
3.1. Vβ 6.7 Promoter Is the Most Optimal for TCR Expression.
The map of lentiviral vector pWPT-promotor-α/β chain and
the schematic diagrams representing the structures of the
lentiviral vectors are shown in Figure 1. The promoter-α/β
chain was ampliﬁed by PCR and inserted between MluI
and SalI sites. The mock vector contains TCR α/β chain
without any T-cell-speciﬁc promoter. TCR expression under
four T-cell-speciﬁc promoters was compared by using real-
time PCR, as shown in Figure 2(a). The HSB2 cells were
incubated for 24 hours in medium and then exposed to
each vector at a multiplicity of infection (MOI) of 10. Three
days aftertransduction, the T cells were analyzed by real-
time PCR and Western blotting. We observed that all the
lentiviral vectors were able to transduce the T cells, using
the Luria, Delta, Vβ 5.1, and Vβ 6.7 promoter-containing
vectors. The Vβ 6.7 promoter vector had the highest TCR
at transcriptional level. When the normalized α and β chain
mRNA levels of the Luria promoter group were set at
100.03±21.09 and68.45±23.75, Deltawas46.15±11.01 and
26.54±6.86,Vβ5.1was42.08±6.78and28.76±19.75,andVβ
6.7 was 150.58 ± 32.02 and 102.564 ± 17.75, and mock was4 Clinical and Developmental Immunology
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Figure 1: The map of lentiviral vector pWPT-promotor-α/β chain and the schematic diagrams representing the structures of the lentiviral
vectors. (a) The map of lentiviral vector pWPT-promotor-α/β chain. The promoter-α/β chain was ampliﬁed by PCR and inserted between
Mlu Ia n dSal I sites. (b) The schematic diagrams representing the structures of the lentiviral vectors. All the α/β chains of the anti-LMP2
TCR PL5.05 were driven by individual T-cell-speciﬁc promoter except mock which contains only α or β chains without any promoter
region. Promoter-α chains in diagram forms were the lentiviral vectors designed to express α c h a i nd r i v e nb yV β 5.1, Luria, Delta, and Vβ
6.7 promoters, respectively. Promoter-β chain used Vβ 5.1, Luria, Delta, and Vβ 6.7 promoters to produce the individual β chain.
4.89 ± 3.09 and 4.08 ± 2.98. The mRNA levels of TCR were
consistent with the protein levels used in Western blotting to
detect the protein levels of the TCR α and β chain. Protein
levels of TCR were much higher in the Vβ 6.7 group than
in the other groups (Figure 2(b)). The expression of TCR α
and β chain on the HEK293T cells and HepG2 cells (human
hepatocellular carcinoma cell line) were almost not detected
(Data not shown). These results suggest that the lentiviral
vectors can express TCR in the T cell lines and PBMCs. Four
diﬀerent promoters have diﬀerent levels of capacity to drive
TCR expression.
3.2. Lentiviral Vectors with Various Promoters Can Transduce
TC e l l sE ﬃciently. HSB2 and PBMCs were infected with
lentiviral vectors having various promoters expressing the
TCR α and β chain at MOI = 1o r1 0 .T h r e ed a y sa f t e r
infection, expression of the TCR α chain was detected in
the CD3+ T cells by FACS with a Flag tag antibody. At
MOI = 1, the TCR α chain positivities from CD3+ cells
were 16.76 ± 4.62%, 34.15 ± 3.71%, 42.08 ± 6.03%, and
58.58 ± 5.02% under Luria, Delta, Vβ 5.1, and Vβ 6.7,
respectively. At MOI = 10, the positive TCR α chain was
23.42 ± 10.63%, 47.14 ± 4.53%, 46.33 ± 2.96%, and 60.46 ±
5.41%, under Luria, Delta, Vβ 5.1, and Vβ 6.7 T-cell-
speciﬁc promoters of CD3+ cells, respectively (Figure 3(a)).
The Vβ 6.7 group had the highest transducing eﬃciency,
as evidenced by means of 58.58% and 60.46% positive at
MOI = 1 or 10. We next checked the LMP2-TCR expression
by ﬂow cytometric analysis. As shown in Figure 3(b), 51.3%
or 62.1% of the HSB2 or PBMC cells, respectively, wereClinical and Developmental Immunology 5
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Figure 2:ComparisonoflentiviralvectorconstructionsdrivenbydiﬀerentT-cell-speciﬁcpromoters.(a)ComparisonofmRNAlevelofTCR
PL5.05 α and β chain under diﬀerent T-cell-speciﬁc promoters by using quantitative RT-PCR. The number on each column corresponds to
themeannumberofmRNAnormalizedbyGADPHmRNA,andtheverticalbarrepresentstheSD.(b)Conventionalwesternblotassaysfrom
HSB2 cells which are infected with lentivirus containing TCR α and β chains driven by Vβ 6.7, Delta, Vβ 5.1, and Luria promoters. Either
Flag or Myc fusion proteins were transferred to membranes and incubated with the indicated antibody. Approximately, ﬁfty micrograms of
each protein per lane were applied for electrophoresis. Equal protein loading was controlled by staining of GAPDH (lower panel). Statistical
analysis was determined using the Student t-test with ∗P<0.05, compared to other groups.
positive when conﬁrmed by the result of FACS. The empty
lentiviral vector-infected control group showed no TCR
5.05 expression. To test the stability of TCR expression on
the surface of the cytoplasm membranes, we checked the
expression of TCR 1 and 7 weeks after transduction by
using FACS. Our experiments showed that there were no
signiﬁcant changes in the TCR expression levels in either the
HSB2 cells or the CD3+ T cells transduced by all 4 lentiviral
vectors. However, the Luria group had the lowest, and the
Vβ 6.7 group had the highest transduction eﬃciency 1 week
and 7 weeks after transduction (Figures 3(c) and 3(d)). The
percentage of TCR-positive cells in CD3+ group 1 week after
transduction is similar to that of the 3-day transduction
experiment described above.
3.3. Transduced PBMCs Can Speciﬁcally Lyse HLA-A2/LMP2,
Expressing Target Cells. To assess the recognition of tumor
antigens by lentivirus-transduced PBMCs and CD8+ T cells,
the cells were cocultured with the indicated tumor cell
lines or T2 cells pulsed with LMP2426–434 (CLGGLLTMV)
(CLGG). After sorting, the CD8+ c e l l sw e r ec o l l e c t e da n d
incubated with target cells at eﬀector-to-target-cell ratios
(E:T) = 50:1, 25:1, and 5:1. As shown in Figure 4(a), the
Vβ 6.7 group has the highest lytic activity when using all 3
E:T ratios. To test the speciﬁcity of cytotoxicity, we chose
the Vβ 6.7 lentiviral vector infected with PBMCs and CD8+
groups against diﬀerent targeting cells. The results showed
that Vβ 6.7 lentiviral vector-infected PBMCs could lyse T2-
CLGG and LCLs eﬀectively moderately but could not lyse T2
cells, T2 cells loaded with nonrelated peptides (T2-LLWT),
and K562 cells (Figure 4(b)).
We also measured the IFN-γ levels in the supernants
of the transduced-PBMC cytotoxicity experiments. All 4
promoter-containing lentiviral vector groups which trans-
duced PBMCs secreted high levels of IFN-γ (>500pg/mL)
when incubated with CLGG and LCLs but secreted very low
levels of IFN-γ when incubated with T2, T2 LLWT, or K562
cells (Figure 4(c)). These results further conﬁrmed that the
lysis is speciﬁc.
We next tested the cytotoxicity of Vβ 6.7-transduced
CD8+ T cells against the targeting cells described above.
Similar to the result involving PBMCs, the transduced CD8+
T cells had a higher cytotoxicity against the T2-CLGG
and LCL, but minimal eﬀects on T2-LLWT, T2, and K562
cells (Figure 4(d)). LCLs are EBV-transduced B lymphocytes
which belongs to type III infection, expressing nine EBV
genes encoded by the virus including LMP2. The results
indicated that Vβ 6.7 lentiviral transduced T cells can
speciﬁcally lyse HLA-A2-restricted tumor cells expressing
EBV-LMP2.
4.TransducedCD8+ CellsCanSlow
the GrowthRateof LMP2-Expressing
CNETumors inMice
CNE tumor cells stably expressing HLA-A2 and LMP2 were
inoculated subcutaneously at 5 × 105 cells per mouse to
establishthetumormodel.Tendayslater,thepeptide-pulsed,
lentiviral vector-transduced CD8+ c e l l sw e r ei n f u s e dv i at h e
tail vein. The tumors were monitored daily till the tumor
reached 1cm2, when the mouse was sacriﬁced. Each group
of the transduced CD8+ cells was shown to slow or abolish6 Clinical and Developmental Immunology
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Figure 3: Expression of TCR α and β chains in the HSB2 cells and PBMCs. (a) The PBMCs were incubated with lentivirus containing
EBV-LMP2 TCR α and β chains driven by T cell-speciﬁc promoters at MOIs of 1 and 10. Three days aftertransduction, cells were collected
and stained for CD3 mobilization as a measure of TCR α chain expression. (b) Photographs of ﬂow cytometric analysis for TCR α chain
expression in HSB2 cells (top) and PBMC cells (bottom). The cells were infected with recombinant lentivirus or control empty lentivirus
at MOI of 10 for 3 days. TCR staining was performed by using anti-TCR α chain antibody (prepared from our lab) followed by PE-labeled
second antibody. (c) Percentage of TCR α chain-positive cells in transduced HSB2 cells 1 week and 7 weeks after infection at MOI of 10.
(d) Percentage of TCR α chain-positive cells in transduced CD3+ cells 1 week and 7 weeks after infection. PBMCs stimulated with IL-2
plus OKT3 for 24hr were infected with the lentivirus at an MOI of 10. After 1 week, the PBMCs were analyzed by FACS for TCR α chain
expression and then maintained in culture with IL-2 for 7 weeks for reanalysis for TCR α chain-positive cells.
the established tumors in the mouse model (Figure 5(a)).
There were no statistically signiﬁcant diﬀerences between the
antitumor eﬀects of the 4 promoter groups. All immunized
groups were signiﬁcantly diﬀerent when compared with
the saline and mock groups (Figure 5(b)). The mice were
deemed dead when the tumor reached 1cm2. None of the
mice in the Vβ 6.7 group died, and only 1 mouse died in
each of the Luria, Delta, and Vβ 5.1 groups. All the mice
in the saline group died 36 days after inoculation. These
resultsdemonstratedthetherapeuticeﬀectsofreinfusedCTL
transduced with lentiviral vectors containing the speciﬁc
TCR.Clinical and Developmental Immunology 7
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Figure 4: Transduced PBMCs speciﬁcally lyse HLA-A2-restricted LMP2-expressing target cells. (a) Lytic activity of CD8+ cells selected from
PBMCs transduced with lentivirus containing LMP2-TCR at indicated eﬀector-to-target cell ratios (E:T) was demonstrated in an LDH-
release assay. Targets were HLA-A2-restricted T2 cells loaded with CLGG. Results are expressed as percent of the value measured in control
cells incubated with the same volume of medium (mean ± SD of 3 replicates). Lytic activity of PBMCs (b) or CD8+ cells (d) selected from
PBMCs transduced with lentivirus-containing LMP2-TCR driven by T-cell promoter Vβ 6.7 at indicated E:T was demonstrated in an LDH-
release assay. Targets were HLA-A2-matched T2, T2-CLGG, LCL, T2-LLWT, and exceptional K562 cells. All ﬁgures are representative of 3
or more experiments using the same PBMC donor. (c) Levels of IFN-γ being released into the media from transduced PBMC eﬀectors in
the lysis assay above. PBMCs expressing LMP2-TCR were cocultured for 16hr with the indicated target cells. The concentration of IFN-γ
secreted into the medium was measured in an ELISA kit.
5. Discussion
AdoptiveT-cellimmunotherapyremainsanactiveareainthe
correction of birth defects and the treatment of malignan-
cies [26–28, 30, 31]. Unlike traditional immunotherapeutic
approaches such as use of vaccine or antitoxin, adoptive T-
cell immunotherapy is speciﬁc, repeatable, and much more
eﬀective. Adoptive T-cell therapy has advanced from simple
ex vivo expansion of therapeutic T cells to gene-modiﬁed
T cells. As the most important functional molecule of T
cells,speciﬁcTCRhasbeenclonedfromeﬀectiveandspeciﬁc
T-cell clones and transduced into modiﬁed T cells, which
may express a large quantity of cytokines or costimulating
receptors to boost function of the T cells [42–47].
The EBV-associated tumor is a potential target for
adoptive T-cell immunotherapy because of its latent antigen
expression proﬁle. Orentas et al. reported that, by using
SAMEN retroviral vector, they could demonstrate the ability8 Clinical and Developmental Immunology
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Figure 5: Signiﬁcantly reduced tumor burden and enhanced tumor-free survival in nude mice implanted with LMP2-expressing tumors
after infused with transduced T cells. (a) Tumor mouse model was established as described. After 7 days, mice were infused with diﬀerent
lentiviral transduced T cells twice at a 1-week interval. PBS-immunized mice were used as control. Tumor growth was recorded twice a week.
Tumor sizes are expressed as the average of two perpendicular diameters of the tumor. Graphs show mean ± SE; ∗P<0.05; n = 8/group.
(b) Comparison of survival times of tumor-bearing mice infused with T cells ex vivo transduced by lentivirus containing LMP2-TCR α and
β chains driven by various T-cell promoters. Tumor burden was monitored on a weekly basis. Signiﬁcant diﬀerences were observed for all
transduced T-cell vaccination group. ∗P<0.01; n = 14/group. Note: tumor growth rates and survival times were discontinued when the
tumor reached 1cm2 and the mouse was sacriﬁced.
to transfer CTL activity from an LMP2 peptide-speciﬁc
CTL clone to a stimulated PBMC population. These TCR-
transduced PBMCs showed speciﬁc immunoactivity against
LMP2 targets [36]. Here, we continued this work and
attempted to develop an eﬀective lentiviral-based TCR trans-
duction system for future clinical practice. Compared with
retroviral vectors, lentiviral vectors have many advantages
including the ability to transduce minimally stimulated
PBMCs, and they have a potentially safer integration site
preference[48,49].Ourresultsshowedthatlentiviralvectors
caneﬀectivelytransducePBMCsand CD3+ cells with LMP2-
speciﬁc TCRs using 4 diﬀerent T-cell-speciﬁc promoters.
Using highly active T cell promoters to drive TCR α
and β chains has been reported by many groups to evaluate
diﬀerent combinations of promoters. It has been shown
to express that multiple protein subunits, viral vector, and
promoters are required intensive optimization [50, 51]. We
used LMP2-speciﬁc TCRs to compare 4 diﬀerent promoters
in lentiviral vectors. TCR α and β chains are driven by each
promoter independently. Our results showed that, although
lentiviralvectorsofthevariouspromotersexpressTCR αand
β chains at diﬀerent levels, all groups of transduced CD8+
cells dramatically slowed or abolished the growth of LMP2-
positive tumors. These results indicate that the transducing
eﬃciency of lentiviral vectors containing diﬀerent promoters
does not aﬀect the antitumor activity of CTLs. In future
studies, we hope to emphasize the expansion of functional
CTLs after selection rather than switching promoters to
achieve higher transduction eﬃciency.
We have demonstrated that, for a single promoter, Vβ
6.7 is relatively superior to other promoters. Since our work
solely compared T-cell-speciﬁc promoters, we could not
exclude the possibility that others may have more powerful
functions. Jones et al. generally compared speciﬁc and
nonspeciﬁc promoters, which gave a comprehensive picture
of promoter selection and combination [51]. We believe that
the trend of adoptive T-cell immunotherapy is to develop
safer and more eﬀective vectors to engineer T cells. The
priority is still safety. A speciﬁc T-cell promoter can limit
the expression of transgenes in a relatively small subset of
cells,soitistheoreticallysafe.Ourstudyprovidessuggestions
for future designing of lentiviral vectors in adoptive T-cell
immunotherapy.
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